In the future, we need to examine the in vivo anti-tumor effect of PD-1-disrupted EvCAR-T cells on xenografted GBM in highly immuno-incompetent mice, such as NOG (non-obese diabetes/severe combined immune-deficient/IL-2 receptor gamma null) mice. The gene discussed is PDCD1; the disease is neoplasm.